Analyst
UBS
Equibles does not estimate personal net worth.
Olivier Calvar is recorded as Analyst at UBS. Olivier Calvar has spoken on 4 earnings calls across 3 companies, most recently for Gerresheimer AG on August 27, 2026. Those appearances were for SCHOTT Pharma AG & Co. KGaA, Gerresheimer AG and BEFESA S.A. ORD. O.N.. The companies whose calls Olivier Calvar spoke on are classified in the Healthcare and Industrials sectors.
“Basically, you've posted in Q1 last year 7 million EBITDA. You did 70 million over the full year. So just wanted to understand how the year shaped up last year, right?”
“I just wanted to firstly put the sort of reiteration of the full year guidance in perspective. You know, is your expectation in DDS overall still that sort of both glass and polymer are flat on a full year basis?”
“I have one question for you, Andreas, and one for Reinhardt. Maybe, Andreas, you know, have there been any changes to demand in core DCS? I think it was up probably low single digit organically in the quarter.”
UBS
Analyst
Transcript header (unverified)
SCHOTT Pharma AG & Co. KGaA
Medical Instruments & Supplies · Healthcare
Gerresheimer AG
Medical Instruments & Supplies · Healthcare
BEFESA S.A. ORD. O.N.
Waste Management · Industrials
Gerresheimer AG Publication Preliminary Q1 2026 results / Veröffentlichung Vorläufige Ergebnisse Q1 2026
Gerresheimer AG
H1 2026 Interim Report & Conference Call
BEFESA S.A. ORD. O.N.
Half-year report (H1 2026)
SCHOTT Pharma AG & Co. KGaA
Quarterly statement (Q1 2026)
SCHOTT Pharma AG & Co. KGaA
